# Nuclide record aaa817 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/aaa817/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "aaa817" ;
  schema:name "AAA817"@en ;
  schema:alternateName "[225Ac]Ac-PSMA-617"@en ;
  schema:description "AAA817 is an experimental radioligand therapy from Novartis Pharmaceuticals in phase 3 trials for prostate cancer, aimed at PSMA."@en ;
  schema:url <https://nuclide.cc/drugs/aaa817/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=AAA817> ;
  nuclide:status "phase-3" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:modality "radioligand" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06855277/>, <https://nuclide.cc/trials/nct06780670/> .